Further lipidomics and subsequent receiver operating characteristic (ROC) analyses where MS patients were compared to a subgroup of inflammatory neurological diseases, showed that ASM activity in the CSF might be considered as an interesting biomarker for MS that is able to discriminate disease state, independent of other inflammatory and neurological conditions. This evidence concerns the gene SMPD1 and myeloid sarcoma.